Dengue therapeutics consortium 2025: a global collaboration in action.
| Title: | Dengue therapeutics consortium 2025: a global collaboration in action. |
|---|---|
| Authors: | McBride A; University of Oxford, Oxford, UK.; Chanh HQ; Oxford University Clinical Research Unit Vietnam, Ho Chi Minh City, Vietnam.; Trieu HT; Paediatric Intensive Care Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.; Tran HB; Oxford University Clinical Research Unit Vietnam, Ho Chi Minh City, Vietnam.; Anderson KB; State University of New York Upstate Medical University, Syracuse, New York, USA.; Aogo RA; Viral Epidemiology and Immunity Unit, National Institute of Allergy and Infectious Diseases Laboratory of Infectious Diseases, Bethesda, Maryland, USA.; Avirutnan P; Mahidol University, Bangkok, Thailand.; Tran LHB; Oxford University Clinical Research Unit Vietnam, Ho Chi Minh City, Vietnam.; Chan XH; University of Oxford, Oxford, UK.; Chandra R; Novartis Pharmaceuticals, Basel, Switzerland.; Chang A; The George Washington University, Washington, District of Columbia, USA.; Chia PY; Tan Tock Seng Hospital National Centre for Infectious Diseases, Singapore.; Daniel V; Drugs for Neglected Diseases initiative South-East Asia, Federal Territory of Kuala Lumpur, Malaysia.; Demidova A; Independent Researcher, Limassol, Cyprus.; Consuegra Rodriguez MP; Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga, Colombia.; Figueiredo-Mello C; Instituto de Infectologia Emílio Ribas, São Paulo, Brazil.; Garcia-Gallo E; University of Oxford, Oxford, UK.; Garrood W; Wellcome Trust, London, UK.; Tam DTH; Oxford University Clinical Research Unit Vietnam, Ho Chi Minh City, Vietnam.; Jaenisch T; Center for Global Health, Colorado School of Public Health, Aurora, Colorado, USA.; Heidelberg Institute for Global Health, UniversitatsKlinikum Heidelberg, Heidelberg, Germany.; Kain M; Institute of Naval Medicine, Alverstoke, England, UK.; Katzelnick L; Viral Epidemiology and Immunity Unit, National Institute of Allergy and Infectious Diseases Laboratory of Infectious Diseases, Bethesda, Maryland, USA.; Lam PK; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.; Leopold SJ; Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand.; Lim C; Clinical Monitoring Research Program Directorate, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.; M Siqueira A; Drugs for Neglected Diseases Initiative, Geneva, Switzerland.; Malavige GN; Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.; Malik S; Drugs for Neglected Diseases Initiative, Geneva, Switzerland.; Merson L; Public Health Department, Institut Pasteur de Dakar, Dakar, Senegal.; Meyer-Andrieux I; Novartis Pharmaceuticals, Basel, Switzerland.; Moorman N; The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Neal A; National Institutes of Health, Bethesda, Maryland, USA.; Nguyen NM; Oxford University Clinical Research Unit Vietnam, Ho Chi Minh City, Vietnam.; Ong HC; Universiti Malaya, Federal Territory of Kuala Lumpur, Malaysia.; Pett S; Medical Research Council Clinical Trials Unit at University College London, London, UK.; Rojas-Garrido E; Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga, Colombia.; Schilling W; Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand.; Shahrin L; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.; Sjo P; Drugs for Neglected Diseases Initiative, Geneva, Switzerland.; Syed Omar SF; Universiti Malaya, Federal Territory of Kuala Lumpur, Malaysia.; Teixeira M; Center for Advanced and Innovative Therapies, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Tirupakuzhi Vijayaraghavan BK; Critical Care, Apollo Hospital Chennai, Chennai, India.; Villar L; Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga, Colombia.; Vuong NL; Oxford University Clinical Research Unit Vietnam, Ho Chi Minh City, Vietnam.; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.; Waickman A; State University of New York Upstate Medical University, Syracuse, New York, USA.; Wills B; University of Oxford, Oxford, UK.; Kestelyn E; University of Oxford, Oxford, UK.; Oxford University Clinical Research Unit Vietnam, Ho Chi Minh City, Vietnam.; Watson J; University of Oxford, Oxford, UK.; Munblit DB; King's College London, London, UK.; Department of Paediatrics and Paediatric Infectious Diseases, I M Sechenov First Moscow State Medical University, Moscow, Russian Federation.; Yacoub S; University of Oxford, Oxford, UK.; Oxford University Clinical Research Unit Vietnam, Ho Chi Minh City, Vietnam. |
| Source: | BMJ public health [BMJ Public Health] 2026 Jan 12; Vol. 4 (1), pp. e004043. Date of Electronic Publication: 2026 Jan 12 (Print Publication: 2026). |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 9918697578906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2753-4294 (Electronic) Linking ISSN: 27534294 NLM ISO Abbreviation: BMJ Public Health Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [London] : BMJ Publishing Group, [2023]- |
| Abstract: | Dengue is a global health emergency, with annually increasing case numbers that overwhelm healthcare systems, an ever-expanding range of the mosquito vector, and no antiviral or host-directed treatments proven to alter the course of disease. This article reports on a meeting of the Dengue Therapeutics Consortium, which included attendees from 19 countries with backgrounds in basic science, clinical research, drug development, industry, clinical trial methodology and policy. We summarise the current state of dengue therapeutics research and highlight the necessary steps to ensure that patients have equitable access to affordable and effective treatments. We review the antiviral pipeline, including novel and repurposed antiviral candidates, and we propose both human challenge and rate of viral clearance studies as methods to rapidly screen for antiviral activity prior to larger phase 3 clinical trials. We review ongoing phase 2 and phase 3 clinical trials to evaluate repurposed host-directed therapies for patients with moderate and severe disease, and we suggest considerations for future trial design, such as factorial randomisation and the use of a core outcome set to maximise efficiency and enable evidence synthesis by meta-analysis. We consider that multisectoral collaboration will be essential to achieve our aim of effective treatments for dengue. This will include drug development aligned to target product profiles, conduct of clinical trials with endpoints acceptable to both patients and regulators and sustained commitment from the pharmaceutical industry, non-profit initiatives and policymakers to ensure that effective treatments reach those who need them the most.; (Copyright © Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. Published by BMJ Group.) |
| Competing Interests: | PA reports receiving the Joint PMU-DFG Research grant ((IO)R0166411001) from the Programme Management Unit for Human Resources and Institutional Development, Research and Innovation. She reports receiving cofunding research grants ((IO)R016536001 and P-20-52570) from the National Science and Technology Development Agency (NSTDA) and the Faculty of Medicine Siriraj Hospital, Mahidol University. She also received a joint MRC-NSTDA-TRF research grant ((IO)R015936005) and support from the RED programme at the Faculty of Medicine Siriraj Hospital. She has received a Human Infection Challenge Vaccine (HIC-Vac) pump priming round 7 grant ((IO)R016842001) and National Vaccine Institute Fiscal Year 2024 grant ((IO)R016841024). She served on advisory boards for the PLATCOV and AD ASTRA trials and has submitted a petty patent application for anti-NS1 monoclonal antibodies and their functions (ref. no. 2503003156). IM-A and RC are employed by Novartis Pharmaceuticals. GNM led the Global programme of Drugs for Neglected Diseases initiative from June 2022 to 2024 and has received honouraria for webinars conducted for Roche and Thermofisher. She has served as an advisor on dengue for Johnson&Johnson, Novartis, Takeda and Abbott, and is currently President-elect of the International Society of Infectious Diseases. SP holds research grants from EDCTP-2, EDCTP-3, NIHR, Gilead Sciences, ViiV Healthcare, MRC and Janssen-Cilag. She serves as a DSMB member for the TIPAL trial (UK NIHR-funded) and the IMPEDE-PKD trial (NIHR-funded, UK and international sites). BKTV has received funding for a trial of Dexamethasone in patients hospitalised with dengue from the University of Toronto India Foundation and funding from the European Society of Intensive Care Medicine to conduct an observational study of dengue epidemiology. He receives partial salary support from the Wellcome Trust (UK). DBM reports receiving a grant from the Gates Foundation for developing and publishing Core Outcome Sets (INV-963472). SY serves on the scientific committee for the Takeda dengue vaccine programme and has participated in an advisory board for Novartis, for which she has received consulting fees. She is also Chair of the DSMB for a Phase 2 antiviral trial conducted by Novartis. |
| References: | Clin Infect Dis. 2021 Jun 15;72(12):e1074-e1083. (PMID: 33340040); Sci Transl Med. 2022 Oct 26;14(668):eabo5019. (PMID: 36288280); Lancet Infect Dis. 2024 Jan;24(1):36-45. (PMID: 37778363); PLoS Negl Trop Dis. 2024 Mar 27;18(3):e0012071. (PMID: 38536887); Lancet Infect Dis. 2014 Aug;14(8):706-715. (PMID: 24877997); Clin Infect Dis. 2021 May 18;72(10):e586-e593. (PMID: 33462580); J Infect Dis. 2013 May 1;207(9):1442-50. (PMID: 22807519); Adv Biol Regul. 2022 Dec;86:100901. (PMID: 35915043); Nat Microbiol. 2024 May;9(5):1356-1367. (PMID: 38561497); Elife. 2024 Jun 21;13:. (PMID: 38904662); PLoS Negl Trop Dis. 2012;6(9):e1752. (PMID: 23029567); PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785. (PMID: 20706626); J Med Chem. 2024 Mar 14;67(5):4063-4082. (PMID: 38482827); PLoS Negl Trop Dis. 2014 Aug 28;8(8):e3025. (PMID: 25166493); Clin Infect Dis. 2020 May 23;70(11):2247-2255. (PMID: 31188423); Int J Infect Dis. 2023 Sep;134:292-298. (PMID: 37463631); Lancet Infect Dis. 2025 Oct 7;:. (PMID: 41072450) |
| Contributed Indexing: | Keywords: Disease Vectors; Endemic Diseases; Epidemics |
| Entry Date(s): | Date Created: 20260121 Date Completed: 20260121 Latest Revision: 20260123 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12815177 |
| DOI: | 10.1136/bmjph-2025-004043 |
| PMID: | 41561567 |
| Database: | MEDLINE |
Journal Article; Review